Pharmafile Logo
Pharmafocus logo
Advanced Search

FDA accepts Astellas’ sNDA for Cresemba in children

August 11, 2023
Research and Development Astella, FDA, Paediatrics, cresemba

The US Food and Drug Administration (FDA) announced it has accepted Astellas Pharma’s supplemental New Drug Application (sNDA) for Cresemba …

News
towfiqu-barbhuiya-ssz6x-gao0c-unsplash

Sosei Heptares and Cancer Research UK announce first patient dosed in phase 1/2a trial

August 10, 2023
Research and Development Cancer Research UK, Oncology, Sosei Heptares, clinical trial, immunology

Sosei Heptares and Cancer Research UK have announced that the first patient has been dosed in their phase 1/2a clinical …

News

Sunbird Bio and Glympse Bio merge for development of protein-based diagnostic technology

August 10, 2023
Business Services Glympse Bio, Oncology, Sunbird Bio, merger, oncology

Sunbird Bio has announced that it has completed a merger with Glympse Bio, intending to accelerate the development of both …

News

Astellas set to open new life sciences facilities in Cambridge, Massachusetts

August 10, 2023
Business Development Astellas Pharma, Pharmacy, pharmaceutical, science facility

On 9 August 2023, Astellas Pharma announced its plans to open what it has described as a “state-of-the-art life sciences …

News

EureKING planning creation of new biotech company through the acquisition of SCTbio

August 9, 2023
Business Services, Research and Development Pharmacy

On 9 August 2023, eureKING announced it is set to acquire the pharmaceutical company SCTbio which specializes in cell and …

News
heartbeat

Novo Nordisk’s Wegovy reduces risk of cardiovascular events

August 9, 2023
Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide

Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …

News

Oculis announces positive results from phase 3 OPTIMIZE trial

August 9, 2023
Research and Development Oculis, Opthalmology, clinical trial, eyedrops, ocular surgery

Oculis has announced positive topline results from its phase 3 OPTIMIZE trial for its OCS-01 eyedrops, a once daily, high …

News

FDA grants clearance to next phase of Ascentage Pharma’s clinical trial for CLL/SLL treatment

August 8, 2023
Research and Development Ascentage Pharma, CLL/SLL, FDA, Oncology, clinical trial

Ascentage Pharma has announced that the US Food and Drug Administration (FDA) has granted clearance for the phase 3 study …

News

Astex expands collaboration with MSD

August 8, 2023
Business Services Astex pharmaceuticals, Merck, Oncology, collaboration, small molecules

Astex Pharmaceuticals has announced an exclusive worldwide research collaboration and license agreement with MSD (known as Merck in the US), …

News

Amarin’s Vazkepa accepted by SMC for patients with cardiovascular disease

August 8, 2023
Research and Development Cardiology, Vazkepa, cardiovascular disease, pharmaceutical

On 7 August 2023, the Scottish Medicines Consortium (SMC) announced that they had accepted Amarin’s treatment for people with cardiovascular …

News

First oral treatment for women with postpartum depression approved by FDA

August 7, 2023
Research and Development FDA, postpartum depression, treatment, zurzuvae

On 4 August 2023, the US Food and Drug Administration (FDA) approved the use of Zurzuvae for adults with postpartum …

News
Vaccine image

New vaccine research centre opened to prepare for future pandemics

August 7, 2023
Research and Development Immunology, UKHSA, pandemic, vaccine research centre

Ministers have opened a new vaccine research centre at the UK Health and Security Agency’s (UKHSA) Porton Down campus in …

News
eye2

Astellas announces FDA approval for Izervay for GA treatment

August 7, 2023
Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy

Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay (avacincaptag pegol intravitreal solution) for …

News

FDA approves Merck’s Ervebo vaccine for under 18s

August 4, 2023
Research and Development FDA, Immunology, Vaccine, ebolavirus

On 3 August 2023, the US Food and Drug Administration (FDA) approved Merck’s Ervebo vaccine for children over 12 months. …

News

Evox Therapeutics enters agreement for next generation gene therapy for heart disease

August 4, 2023
Research and Development Cardiology, Evox Therapeutics, Icahn Mount Sinai, cvd, gene therapy

Evox Therapeutics has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn …

News

Ionis and Novartis partner for CVD treatment programme

August 4, 2023
Business Services Cardiology, Ionis Pharmaceuticals, License Agreement, Novartis, cvd

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement with Novartis, aiming to discover, …

News

Targeted chemotherapy to kill all solid tumours developed in preclinical research

August 3, 2023
Research and Development Cancer, Oncology, chemotherapy, pharmaceutical, tumour

Researchers from the City of Hope organisation in the US have released a study confirming the development of AOH1996, a …

News

FDA approves Taiho’s Lonsurf for metastatic colorectal cancer treatment

August 3, 2023
Medical Communications FDA, Lonsurf, Oncology, colorectal cancer, mCRC, taiho

Taiho Oncology and Taiho Pharmaceutical have announced that the US Food and Drug Administration (FDA) has approved Lonsurf (trifluridine/tipiracil) as …

News
Chemotherapy

FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma

August 3, 2023
Medical Communications ABM Therapeutics, ABM-1310, FDA, Oncology, glioblastoma

ABM Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310. …

News

Biopharmaceutical company EQRx set to be acquired by Revolution Medicines

August 2, 2023
Research and Development EQRx, Pharmacy, biopharmaceutical, pharmaceutical, revolution medicines

On 1 August 2023, Revolution Medicines signed an official agreement confirming the acquisition of the biopharmaceutical company EQRx. The deal …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025